Targeting neurological disease with RNAi

Paul Lingor; Mathias Bähr

doi:10.1039/B701169E

skip RSC | ChemSpider | Feedback

Home > Journals > Molecular BioSystems > Targeting neurological ...

Authors & Referees | Librarians

You do not have JavaScript enabled. Please enable JavaScript to access the full features of the site or access our non-JavaScript page.

Molecular BioSystems

Issue 11, 2007

More about this Journal
Editorial Board
Submit an Article

Follow Journal | |

Journal Home | RSC Journals

Highlight

Previous Article | Next Article

Targeting neurological disease with RNAi

Paul Lingor and Mathias Bähr

Mol. BioSyst., 2007, 3, 773-780

DOI: 10.1039/B701169E
First published on the web 29 Aug 2007

Please wait while Download options loads

Request Permissions

Abstract
Cited by
Related Content

The neuroscientific community rapidly adopted RNA interference techniques as an experimental tool for the dissection of gene function in vitro and in animal models of neurological disease in vivo. Here, we discuss recent advances in the biotechnical implementation of siRNA/shRNA-mediated gene silencing focusing on issues of design, delivery and putative detrimental effects. We then summarize the current use of RNAi in targeting neurological disease models and give an outlook on the implementation of this technique in clinical therapy.

Terms & Conditions|Privacy |Accessibility|ACAP Enabled

Molecular BioSystems

Targeting neurological disease with RNAi

Log in (Free Access)

Log in (Subscriber Access)

Articles By